CN105008931A - 非高密度脂蛋白来源的cvd标志物 - Google Patents

非高密度脂蛋白来源的cvd标志物 Download PDF

Info

Publication number
CN105008931A
CN105008931A CN201480012751.3A CN201480012751A CN105008931A CN 105008931 A CN105008931 A CN 105008931A CN 201480012751 A CN201480012751 A CN 201480012751A CN 105008931 A CN105008931 A CN 105008931A
Authority
CN
China
Prior art keywords
lipid
concentration ratio
subject
sample
tag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480012751.3A
Other languages
English (en)
Chinese (zh)
Inventor
R·拉克松恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zora Biosciences Oy
Original Assignee
Zora Biosciences Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zora Biosciences Oy filed Critical Zora Biosciences Oy
Publication of CN105008931A publication Critical patent/CN105008931A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/02—Triacylglycerols
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
CN201480012751.3A 2013-03-08 2014-03-07 非高密度脂蛋白来源的cvd标志物 Pending CN105008931A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775445P 2013-03-08 2013-03-08
US61/775,445 2013-03-08
PCT/EP2014/054499 WO2014135696A1 (en) 2013-03-08 2014-03-07 Non-high density lipoprotein derived cvd markers

Publications (1)

Publication Number Publication Date
CN105008931A true CN105008931A (zh) 2015-10-28

Family

ID=50236206

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480012751.3A Pending CN105008931A (zh) 2013-03-08 2014-03-07 非高密度脂蛋白来源的cvd标志物

Country Status (6)

Country Link
US (1) US20160018423A1 (https=)
EP (1) EP2965092A1 (https=)
JP (1) JP2016511407A (https=)
CN (1) CN105008931A (https=)
CA (1) CA2903946A1 (https=)
WO (1) WO2014135696A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105748469A (zh) * 2016-02-24 2016-07-13 长沙佰顺生物科技有限公司 一种安塞曲匹辛伐他汀药物组合物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9347960B2 (en) * 2014-06-16 2016-05-24 Zora Biosciences, Oy Ceramides and their use in diagnosing CVD
CA2973116C (en) * 2015-01-09 2023-08-15 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
WO2019119049A1 (en) * 2017-12-20 2019-06-27 Baker Heart and Diabetes Institute Method of predicting drug therapeutic responder status and methods of treatment
CA3122035A1 (en) * 2018-12-06 2020-06-11 Zora Biosciences Oy Biomarkers for cardiovascular events
CN112630344B (zh) * 2020-12-08 2021-12-14 河北医科大学第二医院 代谢标志物在脑梗死中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107519A (zh) * 2004-11-24 2008-01-16 冈崎三代 脂蛋白分析方法
CN101802620A (zh) * 2007-02-22 2010-08-11 特提斯生物科学公司 糖尿病状况的代谢标志物及其使用方法
WO2011161062A2 (en) * 2010-06-20 2011-12-29 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
CN102884435A (zh) * 2009-11-27 2013-01-16 贝克Idi心脏和糖尿病研究院控股有限公司 用于稳定和不稳定心脏病的脂质生物标记物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
DE19756255C2 (de) * 1997-12-17 1999-11-11 Heinrich Wieland Verfahren und Diagnostikprodukt zur Bestimmung von in Lipoprotein enthaltenem Triglycerid
JP4062514B2 (ja) * 2001-01-02 2008-03-19 ザ・クリーブランド・クリニック・ファンデーション ミエロペルオキシダーゼ、心臓血管疾患についての危険性指示因子
EP1234816B1 (de) * 2001-02-23 2004-06-30 Biofrontera Pharmaceuticals GmbH Scyphostatin-Analoga als SMase-Inhibitoren
ES2552371T3 (es) * 2012-05-25 2015-11-27 Zora Biosciences Oy Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101107519A (zh) * 2004-11-24 2008-01-16 冈崎三代 脂蛋白分析方法
CN101802620A (zh) * 2007-02-22 2010-08-11 特提斯生物科学公司 糖尿病状况的代谢标志物及其使用方法
CN102884435A (zh) * 2009-11-27 2013-01-16 贝克Idi心脏和糖尿病研究院控股有限公司 用于稳定和不稳定心脏病的脂质生物标记物
WO2011161062A2 (en) * 2010-06-20 2011-12-29 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALAN R.TALL ET AL: "Studies on the structure of low density lipoproteins isolated from Macaca fascicularis fed an atherogenic diet", 《JOURNAL OF CLINICAL INVESTIGATION》 *
KAHRI J ET AL: "Plasma cholesteryl ester transfer protein activity in non-insulin-dependent diabetic patients with and without coronary artery disease", 《METABOLISM》 *
PHILIPP WIESNER ET AL: "Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry", 《JOURNAL OF LIPID RESEARCH》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105748469A (zh) * 2016-02-24 2016-07-13 长沙佰顺生物科技有限公司 一种安塞曲匹辛伐他汀药物组合物
CN105748469B (zh) * 2016-02-24 2019-07-23 长沙佰顺生物科技有限公司 一种安塞曲匹辛伐他汀药物组合物

Also Published As

Publication number Publication date
WO2014135696A1 (en) 2014-09-12
EP2965092A1 (en) 2016-01-13
JP2016511407A (ja) 2016-04-14
CA2903946A1 (en) 2014-09-12
US20160018423A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
US20240385201A1 (en) Lipidomic biomarkers for atherosclerosis and cardiovascular disease
US12270816B2 (en) Lipidomic biomarkers for identification of high-risk coronary artery disease patients
JP6388284B2 (ja) スタチン治療を受けている冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー
JP6388283B2 (ja) スタチン治療を受けていない冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー
CN105008931A (zh) 非高密度脂蛋白来源的cvd标志物
CN103502820B (zh) 用于他汀引发的肌肉毒性的灵敏检测的生物标志物
Konerman et al. Lipoprotein (a) particle concentration and lipoprotein (a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups
Edel Metabolomic Signature of Human Aortic Valve Stenosis
Kappelle et al. Apolipoprotein B/AI and total cholesterol/HDL cholesterol rafios both predict cardiovascular events in the general populafion independently of non-lipid risk factors, albuminuria and CRP

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151028

WD01 Invention patent application deemed withdrawn after publication